Future-proof your API supply: Partner with Sai Life Sciences
As India’s leading, pure-play CRDMO, Sai Life Sciences serves 18 of the top 25 largest innovator pharma companies. Having tech transferred 16 late-stage projects to our sites from China, Europe and Asia in the last few years, we’re fast becoming a partner of choice in the geographic risk-mitigation strategies of pharma innovators.
Highlights
- Serving 18 of the top 25 largest innovator pharmaceutical companies
- 300+ active customers across US, UK, EU & Japan
- USFDA & PMDA approved manufacturing site in India
- 45 commercial products in current portfolio
- 16 late-stage projects tech transferred to our sites in last 3 years
- 700KL world- class manufacturing capacity for APIs & Intermediates
- Experience in wide range of chemistries
Whatever the stage, we help accelerate your programs
Our R&D and manufacturing sites
To future-proof your API supply, get in touch
Sustainability: Innovation with impact
Sustainability is an integral part of our business and decision-making framework. We are committed to conduct business in a way that it creates positive impact on all our stakeholders and the environment at large.
Read more
Quality at every stage
Our quality system is designed to meet the most stringent global regulatory standards. This enables us deliver products that consistently meet the expectations of the markets we serve, particularly US, EU and Japan.
Read more
News
Sai Life Sciences receives EIRs from USFDA for India R&D & Manufacturing facilities
Sai Life Sciences, the fastest-growing Indian Contract Research, Development and Manufacturing Organization (CRDMO)[1], announced that it has received Establishment Inspection Reports (EIR) from the US Food and Drug Administration (USFDA) for its R&D (Unit II, Hyderabad), and Manufacturing (Unit IV, Bidar) sites in India. The General Good Manufacturing Practices (GMP) audit was conducted at the […]
Read more
